• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Immune Checkpoint Inhibitors for the Therapy of Thymoma.免疫检查点抑制剂用于胸腺瘤的治疗
JTO Clin Res Rep. 2020 Feb 11;1(1):100011. doi: 10.1016/j.jtocrr.2020.100011. eCollection 2020 Mar.
2
Immune-Therapy-Related Toxicity Events and Dramatic Remission After a Single Dose of Pembrolizumab Treatment in Metastatic Thymoma: A Case Report.免疫治疗相关毒性事件和单剂量帕博利珠单抗治疗转移性胸腺瘤后的显著缓解：一例报告。
Front Immunol. 2021 Apr 15;12:621858. doi: 10.3389/fimmu.2021.621858. eCollection 2021.
3
Association Between the Occurrence and Spectrum of Immune-Related Adverse Events and Efficacy of Pembrolizumab in Asian Patients With Advanced Urothelial Cancer: Multicenter Retrospective Analyses and Systematic Literature Review.亚洲晚期尿路上皮癌患者免疫相关不良事件的发生和谱与帕博利珠单抗疗效的相关性：多中心回顾性分析和系统文献复习。
Clin Genitourin Cancer. 2021 Jun;19(3):208-216.e1. doi: 10.1016/j.clgc.2020.07.003. Epub 2020 Jul 16.
4
Potential Immune-Related Adverse Events Associated With Monotherapy and Combination Therapy of Ipilimumab, Nivolumab, and Pembrolizumab for Advanced Melanoma: A Systematic Review and Meta-Analysis.伊匹木单抗、纳武单抗和帕博利珠单抗单药及联合治疗晚期黑色素瘤相关的潜在免疫相关不良事件：系统评价和荟萃分析
Front Oncol. 2020 Feb 11;10:91. doi: 10.3389/fonc.2020.00091. eCollection 2020.
5
Immune-related adverse events associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system.免疫检查点抑制剂相关的免疫相关不良事件：FDA 不良事件报告系统的更新综合比例失调分析。
Int Immunopharmacol. 2021 Jun;95:107498. doi: 10.1016/j.intimp.2021.107498. Epub 2021 Mar 13.
6
An Investigation of Nine Patients with Gastrointestinal Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors.免疫检查点抑制剂相关胃肠道免疫相关不良事件九例患者的调查。
Digestion. 2020;101(1):60-65. doi: 10.1159/000504647. Epub 2019 Dec 4.
7
Proposed diagnostic and treatment paradigm for high-grade neurological complications of immune checkpoint inhibitors.免疫检查点抑制剂所致高级别神经并发症的拟诊与治疗模式
Neurooncol Pract. 2019 Sep;6(5):340-345. doi: 10.1093/nop/npy039. Epub 2018 Oct 4.
8
Meta-analysis of immune-related adverse events in phase 3 clinical trials assessing immune checkpoint inhibitors for lung cancer.肺癌免疫检查点抑制剂的 3 期临床试验免疫相关不良事件的荟萃分析。
Crit Rev Oncol Hematol. 2021 Jun;162:103351. doi: 10.1016/j.critrevonc.2021.103351. Epub 2021 May 12.
9
Immune-related adverse events and immune checkpoint inhibitor tolerance on rechallenge in patients with irAEs: a single-center experience.免疫相关不良事件和免疫检查点抑制剂再挑战中的耐受：单中心经验。
J Cancer Res Clin Oncol. 2021 Sep;147(9):2789-2800. doi: 10.1007/s00432-021-03610-w. Epub 2021 Mar 28.
10
Elevated Eosinophil Count Following Pembrolizumab Treatment for Non-Small Cell Lung Cancer.帕博利珠单抗治疗非小细胞肺癌后嗜酸性粒细胞计数升高
Cureus. 2021 Jul 8;13(7):e16266. doi: 10.7759/cureus.16266. eCollection 2021 Jul.

本文引用的文献

1
Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma.晚期胸腺癌中抗程序性死亡配体 1（PD-L1）抗体（avelumab）治疗的疗效和耐受性。
J Immunother Cancer. 2019 Oct 21;7(1):269. doi: 10.1186/s40425-019-0723-9.
2
Fatal adverse events in two thymoma patients treated with anti-PD-1 immune check point inhibitor and literature review.两名胸腺瘤患者接受抗 PD-1 免疫检查点抑制剂治疗后的致死性不良事件及文献复习。
Lung Cancer. 2019 Sep;135:29-32. doi: 10.1016/j.lungcan.2019.06.015. Epub 2019 Jul 9.
3
Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial.帕博利珠单抗治疗难治或复发胸腺癌患者的开放性 II 期临床试验。
J Clin Oncol. 2019 Aug 20;37(24):2162-2170. doi: 10.1200/JCO.2017.77.3184. Epub 2018 Jun 15.
4
Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study.派姆单抗治疗胸腺癌患者的单臂、单中心、2 期研究。
Lancet Oncol. 2018 Mar;19(3):347-355. doi: 10.1016/S1470-2045(18)30062-7. Epub 2018 Jan 26.
5
Neuroendocrine tumors of the thymus: the oncologist point of view.胸腺神经内分泌肿瘤：肿瘤学家的观点。
J Thorac Dis. 2017 Nov;9(Suppl 15):S1491-S1500. doi: 10.21037/jtd.2017.08.18.
6
Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial.舒尼替尼治疗化疗难治性胸腺瘤和胸腺癌患者：一项开放标签的2期试验。
Lancet Oncol. 2015 Feb;16(2):177-86. doi: 10.1016/S1470-2045(14)71181-7. Epub 2015 Jan 13.
7
Malignant thymoma in the United States: demographic patterns in incidence and associations with subsequent malignancies.美国的恶性胸腺瘤：发病率的人口统计学模式及其与后续恶性肿瘤的关联。
Int J Cancer. 2003 Jul 1;105(4):546-51. doi: 10.1002/ijc.11099.

Immune Checkpoint Inhibitors for the Therapy of Thymoma.

作者信息

Quilez Alicia, Guillen Edgar F, Sánchez Luisa, Espinós Jaime, González Antonio, Corral Jesus

机构信息

Medical Oncology Department, University Hospital of Puerto Real, Cádiz, Spain.

Nuclear Medicine Department, Clínica Universidad de Navarra, Madrid, Spain.

出版信息

JTO Clin Res Rep. 2020 Feb 11;1(1):100011. doi: 10.1016/j.jtocrr.2020.100011. eCollection 2020 Mar.

DOI:10.1016/j.jtocrr.2020.100011
PMID:34589913
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8474349/
Abstract
摘要